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ABSTRACT
The reference sites of the European Innovation Partnership on Active and Healthy Ageing 
(EIP on AHA) were renewed in 2019. The DG Santé good practice Mobile Airways Sentinel 
networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management 
of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 
4) Community for monitoring and assessment framework, 5) Political, organizational, 
technological and financial readiness, 6) Contributing to European co-operation and 
transferability, 7) Delivering evidence of impact against the triple win approach, 8) 
Contribution to the European Digital Transformation of Health and Care and 9) scale of 
demonstration and deployment of innovation
Keywords: Mobile applications; rhinitis; asthma; health; healthy aging
INTRODUCTION
Chronic respiratory diseases (CRDs) are among major chronic diseases in terms of 
prevalence and burden.1 Most cases of asthma and rhinitis occur early in life and persist 
across the life cycle. A life course is needed to prevent and manage CRDs in old people. 
Mobile Airways Sentinel NetworK (MASK)2,3 was used as a proof-of-concept for chronic 
disease care across the life cycle for the renewal of the Reference Site of the European 
Innovation partnership on Active and Healthy Ageing (EIP on AHA) Contre les Maladies 
Chroniques pour un Vieillissement Actif (MACVIA).4 MASK involves professionals and 
patients focusing on EIP on AHA priorities. It proposes real-world integrated care pathways 
(ICPs) centered around the patient with rhinitis and asthma multimorbidities. MASK is a 
good practice (GP) of DG Santé in the Digital Transformation of Health and Care presented 
in Ispra (December 15, 2018)3 for change management.5 CRDs, such as asthma and rhinitis, 
often start early in infancy and can persist throughout life. There are specific problems in old 
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Aligning the Good Practice MASK 
With the Objectives of the European 
Innovation Partnership on Active and 
Healthy Ageing
people associated with a modification of the disease, multimorbidities (allergic and non-
allergic) and co-medications (allergic and non-allergic). MASK is devoted to the management 
of rhinitis and asthma across the life cycle focusing on old adults.
The Widening the support for large scale uptake of Digital Innovation for Active and 
Healthy Ageing (WE4AHA) coordination and support action (https://ec.europa.eu/digital-
single-market/en/news/we4aha-enabling-large-scale-uptake-digital-innovation-active-
and-healthy-ageing), funded under the H2020 Programme, aims to advance the effective, 
large-scale uptake and impact of Digital Innovation for Active and Healthy Ageing (AHA), 
building on a comprehensive set of support and promotion services. Through WE4AHA's 
centralized administration, coordination and external communication activities, the relevant 
stakeholders have been called upon to further develop the EIP on AHA and to promote 
and implement its horizontal initiatives: innovation to market (I2M), Blueprint Digital 
Transformation of Health and Care for the Ageing Society (Blueprint) and the monitoring 
and assessment framework (MAFEIP) for the EIP on AHA (Fig. 1).
The present paper summarizes the alignment of MASK to the EIP on AHA objectives.
THE MOBILE HEALTH (MHEALTH) GOOD PRACTICE MASK
MASK, the phase 3 Allergic Rhinitis and its Impact on Asthma (ARIA) initiative,6 aims 
to reduce the global burden of allergic rhinitis (AR) and asthma multimorbidities, giving 
the patient and the health care professional simple tools to better prevent and manage 
respiratory allergic diseases in a cost-effective manner. First, it includes a freely available 
MASK app (MASK-air®, formerly the Allergy Diary, Android and iOS).7 Secondly, there is 
an interoperable electronic clinical decision support system (e-CDSS).8 Thirdly, there is an 
interoperable questionnaire for physicians available online.9
MASK is scaled up using the EIP on AHA strategy.10 It is supported by several EU grants and 
is a Global Alliance against CRDs (GARD; World Health Organization [WHO])11 research 
demonstration project. It is a GP of DG Santé on the digital transformation of health and care.3,12
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Fig. 1. Cross-cutting initiatives of 2017-2019 EIP on AHA. 
EIP on AHA, European Innovation Partnership on Active and Healthy Ageing; MAFEIP, monitoring and assessment 
framework.
MASK-air®
MASK-air® is an information and communication technology (ICT) system centering 
around the patient2,3,13-15 operational in 23 countries and 17 languages. It uses a treatment 
scroll list which includes all of the medications customized for each country, as well as a 
visual analogue scale (VAS), to assess rhinitis control (global allergy impact, nose, eyes and 
asthma), sleep and work productivity.16 MASK-air® is in line with the GDPR,17 in particular for 
geolocation.18 MASK-air® will be combined with prediction on allergen season and pollution 
exposure (impact of air POLLution on Asthma and Rhinitis, EIT Health [POLLAR] funded 
project)15,19 in 2019 (Table).
• App: 30,000 users, 23 countries, 17 languages
• 250,000 days of VAS report
• No missing data due to app structure
• Tested with patients and physicians for acceptability
• GDPR including geolocation
• Follows the recommendations of ICPs for airway diseases (AIRWAYS ICPs)15
• From a validated “research” tool (2004-2018) to large scale deployment (2019-)
•  Validation with COnsensus-based Standards for the selection of health Measurement 
INstruments guidelines20
• Found to be the most relevant app for rhinitis and asthma21,22
• Assessment of data quality (Bedard, in preparation)
• Baseline characteristics23
• Work productivity16
• EuroQOL (EQ-5D) and the work productivity and activity impairment allergy-specific7
• Novel phenotypes of allergic diseases24
• Adherence to treatment25,26
• Novel approaches to inform the efficacy of treatment25
• Sleep23
• Patient's organizations and scientific societies involved
• Presented during WHO, EU ministerial meetings and EU parliament meetings12,27-29
•  Next-generation care pathways meeting (December 3, 2018) with the EIP on AHA, POL-
LAR and GARD
• Over 70 MASK papers in 16 languages
• Dissemination according to the EIP on AHA10
Electronic clinical decision support system for rhinitis
The interoperable e-CDSS8 is based on an algorithm designed by the ARIA expert group30 and 
is validated using real-world evidence (RWE).31 This e-CDSS is for use on tablets and is for 
pharmacists and physicians. The e-CDSS is currently being tested on pharmacists in Portugal 
and Australia.
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Table. MASK air®
• GP of the EIP on AHA follows CHRODIS59
• GP on digitally enabled, integrated, patient-centred care endorsed by DG Santé4
• Based on several EU grants (MeDALL, GA2LEN56) including—in 2018—POLLAR,21 DHE Twinning (digital transformation of health).
• Reported in the JRC Science and Policy Reports on Strategic Intelligence Monitor on Personal Health Systems phase 37
• One example of the WHO-ITU “Be He@lthy, Be Mobile” handbook on how to implement mBreatheFreely for asthma and COPD50
• GARD (WHO alliance) demonstration project
MASK, Mobile Airways Sentinel NetworK; GP, good practice; EIP on AHA, European Innovation Partnership on Active and Healthy Ageing; the WHO, World Health 
Organization; JRC, Joint Research Center; MeDALL, Mechanisms for the Development of ALLergy; POLLAR, impact of air POLLution on Asthma and Rhinitis, EIT 
Health; ITU, International Telecommunication Union; COPD, chronic obstructive pulmonary disease; GARD, Global Alliance against CRDs.
Web-based physician's questionnaire for rhinitis and asthma
An interoperable questionnaire for physicians is available online on the European Forum 
for Research and Education in Allergy and Airway Diseases (Euforea) website (https://
www.euforea.eu). Over 1,000 patients have been enrolled in the 2017 Twinning using the 
questionnaire. They are then followed up using the app.9
MANAGEMENT OF CARE PROCESSES
Protocols and guidelines have been developed by the ARIA expert group since 1999, in 
collaboration with the WHO (WHO Collaborating Center for Rhinitis and Asthma)6,32 using 
the grading of recommendations, assessment, development and evaluations (GRADE) 
approach33,34 and including those for severe asthma developed with the WHO.35 A new 
approach has been made to develop guidelines tested with RWE.29,31 IT solutions have been 
given major focus.3
Education and training: The ARIA expert group consists of 600 members in 89 countries 
with education and training in most countries or clusters.36 Education is performed in each 
country by different university members (including all health care professionals37) with health 
care professionals in private practice and with patients' organizations.
Standardization, interoperability and financing: the protocols are standardized and operate 
in over 40 countries globally. They have been endorsed by several governments and are being 
used for the registration of treatments (European Medicine Agency; EMA). They have been 
used by a Twinning in more than 20 countries.9
BLUEPRINT OF DIGITAL TRANSFORMATION
The European “Blueprint on Digital Transformation of Health and Care for the Ageing 
Society” reflects the common policy vision of European policy makers, professional and 
civil society organizations, and industry. As a shared policy vision, the Blueprint guides the 
efforts of the EIP on AHA Action Groups and Reference Sites. The Blueprint is essential for 
mobilizing investments and guaranteeing the commitment of all actors including industrial 
players, regional authorities, professional and civil society organizations, and multi-
stakeholder platforms.
Data analytics for predictive risk stratification and prevention
MASK-air® data available for 3,000 users have shown new phenotypes of daily symptoms, 
including an unrecognized pattern of allergic multimorbidity, which will be very useful for a 
new stratification of allergic individuals.24 These results obtained using a big data approach in 
days were confirmed in canonical epidemiologic studies in patients.38-41
Pro-active prevention through empowerment, self-management, monitoring 
and coaching
The best practices/solutions available for targeting persons' needs. Outcomes and high 
impact on patients and the health care system. MASK-air® results in around 10,000 users 
show that rhinitis patients are poorly adherent to treatment and that new approaches are 
needed to monitor the efficacy of the treatments.26 MASK is a GP of DG Santé on digitally 
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enabled, patient-centered care and is promoting patients' empowerment in collaboration 
with patients' organizations to identify strategies for prevention and self-management.3
Digital solutions for integrated care
AIRWAYS ICPs have proposed to develop care pathways for airway diseases using mHealth. 
This was achieved by MASK whereby next-generation care pathways were developed during 
a POLLAR-GARD meeting (Pasteur Institute, December 3, 2018) including next-generation 
guidelines that embed RWE.27,28
Regions with positive experiences willing to provide the necessary 
knowledge and support to scale up and deploy across Europe
During the past 20 years, ARIA has had a major implementation strategy: to deploy the 
existing knowledge globally. The ARIA pocket guide has been translated into 52 languages. 
The same approach has been applied to MASK which is scaled up using the EIP on AHA 
procedures. 10 MASK has been published in 17 languages, and the Executive Summary is 
expected to be published in 25 countries by the end of 2020. MASK has a specific emphasis 
on the transfer of innovation across centers of the EIP on AHA. A first Twinning based on 
MASK was found to be the most mature and included 20 countries.9 A second Twinning with 
32 centers has been proposed for severe asthma.
Relevant interactions
The GP directly involves persons interacting with digital solutions and those interacting with 
other key actors who place a special emphasis on interoperability.3
Need of other key actors
General practitioners, nurses, pharmacists, carers, public health authorities and other care 
providers are all involved in the health and care provision for MASK.
High scalability and replication potential
MASK-air® is available in 25 countries (developed and developing) (Fig. 2).
EIP ON AHA, I2M
One of the key challenges in Europe for AHA is the implementation and scaling-up of cross-
border innovative solutions. One of the aims is to support the transformation of health and 
care in the Digital Single Market, thereby reinforcing the links between the development 
of solutions by companies, start-ups and researchers—the supply side. The other aim is to 
bridge a gap with the expectation and need of care providers, policy-makers, insurers and 
other potential buyers of these products and services—the demand side.
The WHO Guide for scaling-up deﬁned the term as “…deliberate eﬀorts to increase the 
impact of health service innovations successfully tested in pilot or experimental projects so 
as to beneﬁt more people and to foster policy and program development on a lasting basis.” 
42 This deﬁnition stresses the importance of recognizing innovative solutions that are ﬁrst 
piloted successfully and then become a mainstream policy.
The purpose of the I2M initiative is to improve the match between the demand and supply 
sides in AHA, by engaging in a dialog and by organizing a series of activities and services 
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that involve the 2 sides of the market (https://ec.europa.eu/eip/ageing/innovation-market-
i2m_en). To make concrete progress on a large-scale uptake and impact of Digital Innovation 
for AHA, a comprehensive set of support and promotion services that are proposed (https://
ec.europa.eu/eip/ageing/library/innovation-market-plan_en). The Plan is addressed to 
both organizations delivering AHA services and solution suppliers. It aims to facilitate 
relationships, mutual understanding and scaling-up, and to increase the impact of innovative 
technology driven solutions in the reference market.
Visibility and awareness activities
Adoption award: MASK has already proposed 2 types of awards
•  An award (platinum, gold or silver) for the members who have had the most important 
activities in the network (Campania, Piedimonte, Puglia, Lithuania, Mexico and Brazil 
received the platinum award).
•  ARIACare on the model of Ucare (for urticaria),43 in collaboration with the Global Allergy 
and Asthma European Network, GA2LEN.44 GA2LEN has launched a program for the 
development, interaction and accreditation of center of reference and excellence in 
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Fig. 2. The ARIACARE digital network.
special areas of allergy embedded in its overall quality management of allergy center 
of excellence. The first chosen area is urticaria. From September 2019, ARIACare will 
accredit and award the center in AR and asthma based on the ARIA study group of 600 
members. The call preparation and the jury are in place. It is expected that 100 centers 
will be awarded globally.
Expanding repository of innovative practices
MASK is an innovative practice in the repository (https://ec.europa.eu/eip/ageing/repository/
macvia-aria-sentinel-network-rhinitis_en). We will include new practices based on the 
expertise of MASK.
Needs showcase and solution platforms
MASK is in the process of creating an online map that provides clear information and 
encourages interactions among the actors in the sector such as a permanent “marketplace.” 
This will enable an easier exchange of information between buyers and suppliers, and will 
facilitate transactions.
Knowledge brokerage and matchmaking services
Matchmaking sessions: MASK has tailored solutions that have been adapted at the regional 
or national level (Argentina, Austria, Australia, Belgium, Brazil, Canada, Columbia, Czech 
Republic, Denmark, Finland, France, Germany, Greece, Italy, Japan, Lithuania, Mexico, 
The Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey and the UK) in 
collaboration with the WHO (GARD demonstration project). For all these countries, the 
language has been translated and adapted. Moreover, Catalan has also been used. This was 
particularly the case for the Twinning.9 Training on AHA innovation adoption is in process as 
part of the POLLAR grant.
Online training for SMEs on private funding, online repository on reimbursement systems 
and online repository on resources and market insights are not yet envisaged.
Transfer activities (Twinning schemes)
Rhinitis and asthma TWINNING 1,000 patients have been enrolled including over 300 old 
people. This TWINNING is fully mature (level 4) and is a success story.57 Analysis is being 
carried out.
Dissemination of MASK
Dissemination strategy. The dissemination strategy follows the proposed strategy and uses 
a 5-step framework for developing an individual scaling-up strategy: 1) what to scale up—1-1) 
databases of GPs, 1-2) assessment of viability of the scaling up of GPs and 1-3) classification of 
GPs for local replication—and 2) how to scale up—2-1) facilitating partnerships for scaling 
up, 2-2) implementation of key success factors and lessons learned, including emerging 
technologies for individualised and predictive medicine. This strategy has already been 
applied to the CRD action plan of the EIP on AHA.10
Networks. The MASK Network includes all countries and regions of the ARIA Network 
participating in MASK. It comprises over 350 active members in 26 countries. The role of 
the network was first to translate all MASK documents in 18 languages, then to continue the 
adaptation of the MASK project and finally to include patients. The members of the network 
also actively participated in the publications. The network is very strong and reactive.
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COMMUNITY FOR MAFEIP
The MAFEIP for the EIP on AHA monitoring framework comprises a web-based tool which 
rests on the principles of Decision Analytic Modeling (DAM) (https://www.mafeip.eu/
the-tool). It is based on a traditional Markov model commonly used in health economic 
evaluations to assess the impact of healthcare innovations in terms of health outcomes and 
resource use (Fig. 3).
In all the Markov models considered, the baseline health state represents the general health 
status of the target population. The disease/impairment health state(s) reflect(s) the health 
status of people who experience the condition of interest (the condition that the intervention 
aims to prevent, relieve or cure). Each health state is defined by an amount of resource use 
and quality of life (utility). This represents the average resource use and quality of life of a 
patient in that health state.
MASK aims to reduce the global burden of AR and asthma multimorbidity in a cost-effective 
manner, giving the patient and the health care professional simple tools to better prevent and 
manage respiratory allergic diseases and to inform policy makers.
AR impairs quality-of-life,45 but NEVER induces death. Thus, the MAFEIP model that has a 
state of death may be difficult to be used for rhinitis. Prof. A. Briggs designed DAM46 and is 
the health economics consultant of the ARIA group.
Discussion is underway with Prof. Briggs to apply the DAM model to MASK and to make it 
applicable to non-lethal chronic diseases. The model for rhinitis will use EQ-5D weekly7 and 
a VAS daily for work and school productivity. There are sufficient data in MASK to perform 
a pilot study. This information will help guide both clinicians and health policy makers.47 A 
pilot study on daily work productivity provides not only proof-of-concept data on the work 
impairment collected with the app, but also data on the app itself, especially the distribution 
of responses for VAS. This supports the interpretation that patients with rhinitis report both 
the presence and the absence of symptoms. We have performed analyses with up to 100,000 
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27 countries
> 130 centers
Fig. 3. The MAFEIP community. 
MAFEIP, monitoring and assessment framework.
days of VAS work. The dissemination plans for MASK include publishing the case studies and 
evidence based on the MAFEIP website.
Using the rhinitis and asthma Twinning data, MASK will follow 1,000 patients enrolled by 
their allergist using an interoperable physician's questionnaire. Then, the results of this study 
will be used to assess all users who have used the app.
POLITICAL, ORGANIZATIONAL, TECHNOLOGICAL AND 
FINANCIAL READINESS
Political
Regional
• MASK is fully supported by the Région Occitanie.
•  In a project on transfer of innovation for severe asthma, the engagement through 
Salerno local health agency of ProMIS@Campania network48,49 will ensure that adoption 
is progressively achieved through a multicentric scale-up pilot. The GP will be adopted 
by Campania Reference Site through Salerno Health Agency. The involvement of 
Campania Region Health Directorate through the Unit for Health Innovation will 
ensure progressive further scale-up to the regional health system through the ProMIS@
Campania network. The National ProMIS network will support dissemination and 
exploitation to other Italian regions.
WHO
•  One example of the WHO-International Telecommunication Union “Be He@lthy, 
Be Mobile” handbook on how to implement mBreatheFreely for asthma and chronic 
obstructive pulmonary disease.50
• GARD demonstration project.11
Political agenda of the EU
•  The EU political agenda is of great importance in supporting the digital transformation 
of health and care for CRDs. The Polish Presidency of the EU Council (2011) prioritized 
the early diagnosis, prevention and control of CRDs in children.51,52 AIRWAYS-ICPs,53 
initiated in 2014 by the EIP on AHA,54 launched a collaboration to develop multi-sectoral 
ICPs. It was a GARD demonstration project.11
•  Euforea proposed a yearly stepwise strategy at the EU or ministerial levels.55 Euforea 
organized an EU Summit in Vilnius, Lithuania (March 2018) to propose multisectoral 
ICPs embedding guided self-management, mHealth and air pollution in CRDs.15 On May 
3, 2019, another Euforea-led meeting (Parliament of Malta) reviewed the results of the 
Vilnius Declaration.
•  POLLAR is focusing on the impact of allergens and air pollution on airway diseases to 
propose novel ICPs integrating pollution, sleep and patient literacy.15
•  The next phase of MASK will be the digital transformation of health and care to sustain 
Planetary health.
Organizational
• GP of the EIP on AHA follows CHRODIS.56
• GP on digitally enabled, integrated, patient-centered care endorsed by DG Santé 3
•  Based on several EU grants (Mechanisms of the Development of ALLergy,57 GA2LEN44) 
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including POLLAR,15 and the DHE TWINNING on the Digital Single Market.
•  Reported in the Joint Research Centre Science and Policy Reports on Strategic 
Intelligence Monitor on Personal Health Systems phase 3.58
Technology Readiness level (TRL)
• App (MASK-air®): TRL9 (ISO 16290:2013 standard59).
•  e-physician questionnaire deployed in 23 countries (available on the Euforea website): 
TRL9.
• Electronic clinical decision support system for the tablet (ARIA e-CDSS): TRL7.
• App (MASK-asthma): TRL8 and tested in 23 countries 4-2020 (TRL9).
• Embedding air pollution and pollen data in MASK-air® (POLLAR): TRL9.
• Embedding artificial intelligence in MASK-air®: TLR3.
Financial readiness
Over the past 5 years, a total budget of around 4 M€ has been obtained, 2.6 M€ from EU 
grants and the rest from private sources.
A start-up company (MASK-air) has been set up.
Other EU grants have been submitted for 2018, and private sources allow the sustainability of 
the project.
A cost business plan has been developed which will allow us to scale up MASK to 50,000 
users by 2020. This will help sustain the project in the longer term and allow us to provide 
further evidence on impact against personal health and well-being, and the economic savings 
through reduced absenteeism from work, etc.
CONTRIBUTION TO EUROPEAN CO-OPERATION AND 
TRANSFERABILITY
Rhinitis and asthma Twinning (2017-2018)
The overarching goal of the EIP on AHA is to enable European citizens to lead healthy, active 
and independent lives while ageing. The aim of this Twinning was to transfer innovation 
from an app developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to 
other reference sites.4 The phenotypic characteristics of rhinitis and asthma multimorbidities 
in adults and the elderly were compared using validated ICT tools (i.e., MASK-air® and 
CARAT: Control of AR and Asthma Test and a physician's questionnaire developed for the 
Twinning) in 22 Reference Sites or regions across Europe. This improved the understanding, 
assessment of burden, diagnosis and management of rhinitis in the elderly by comparison 
with an adult population. Specific objective was: 1) to assess the percentage of adults and the 
elderly able to use the Allergy Diary, 2) to study the phenotypic characteristics and treatment 
over a 1-year period of rhinitis and asthma multimorbidities at baseline (cross-sectional 
study), 3) to follow up using VAS. This part of the study may provide some insight into the 
differences between the elderly and adults in terms of response to treatment and practice, 
and finally 4) to examine work productivity in adults.
Over 1,000 patients were enrolled and the analysis is currently ongoing.
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During the course of the Twinning, new Reference Sites joined the project.
The rhinitis and asthma Twinning was considered to be the most mature Twinning and one 
of the 4 success stories of the Digital Health Europe Twinnings.
MASK website
The MASK website is available in 15 languages (https://www.mask-air.com/).
GARD: target on developing countries
The Twinning is a GARD demonstration project.11 Developing countries have participated 
in the Twinning (Brazil)60 using a strategy for measuring health outcomes and evaluating 
impacts on interventions.61
Two GARD websites exist, one being at the WHO (https://www.who.int/gard/en/), and the 
other (https://gard-breathefreely.org/).
Euforea
Euforea proposed a stepwise yearly strategy at the EU or ministerial levels.62-65 Euforea 
organized an EU Summit in Vilnius, Lithuania (March 2018) to propose multisectoral ICPs 
embedding guided self-management, mHealth and air pollution in CRDs.12 On May 3, 
2019, another Euforea-led meeting (Parliament of Malta) reviewed the results of the Vilnius 
Declaration.
DELIVERING EVIDENCE OF IMPACT AGAINST THE 
TRIPLE WIN APPROACH
The benefits of the triple win are 1) putting the patient in control, 2) saving on costs and 
efficiency, and 3) creating huge opportunities for innovative services and start-ups.
Quality in care (individual benefit)
MASK follows mHealth requirements—proposing smart devices for the self-management 
of diseases and remote monitoring, leading to prevention and management. MASK can help 
healthcare professionals treat patients more efficiently and can enable citizens to become 
more involved in the management of their health and diseases.
• MASK ensured that mHealth apps meet citizens' demands for quality and transparency.
• MASK was tested for quality and compared favorably with other mHealth apps for CRDs.
•  MASK adheres to strict data protection rules. MASK follows GDPR strictly in particular 
for geolocation using the k-anonymity method.
•  MASK attempts to increase user trust and patient safety in order to boost mHealth's 
contribution to high-quality healthcare.
•  MASK attempts to use novel methods about how we use the data. MASK provided real-
world information on rhinitis and asthma.
Research and innovation (industrial benefit)
•  MASK has immediately involved SMEs (Kyomed and ASA, Montpellier, and Peercode, 
NL) to develop the project with a strong business plan for the GP Solution. A new start-
up has been established (MASK-air) initially creating 4 job opportunities. MASK-air will 
develop centers of excellence on digital health for airway diseases (ARIACare-Digital).
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•  MASK obtained an EIT Health project (POLLAR) to develop an innovative solution in 
order to predict the pollen season and its interactions with pollution using a business 
plan and a strong commercial commitment.
Supporting the long-term sustainability and efficiency of health and social 
care systems (institutional and staff benefit)
In process to be done from the GP, the ARIA group (the initiative from which MASK was 
developed) has been endorsed by several governments globally36 and its recommendations 
are used by the EMA.
CONTRIBUTION TO THE EUROPEAN DIGITAL 
TRANSFORMATION OF HEALTH AND CARE (MASK─A GP 
OF DG SANTÉ)
In the context of implementing communication on the digital transformation of health 
and care, DG Santé (the European Commission's Directorate-General for Health and Food 
Safety), in collaboration with the newly established EU Commission Expert Group "Steering 
Group on Health Promotion, Disease Prevention and Management of Non-Communicable 
Diseases (NCD)” (https://ec.europa.eu/health/non_communicable_diseases/steeringgroup_
promotionprevention_en), has supported the scaling-up and wider implementation of GPs 
in the field of digitally enabled, integrated, person-centered care. MASK was one of the 9 GPs 
selected along with chronic disease and Parkinson's disease.3
In all societies, the burden and cost of NCD are increasing rapidly.66 Most economies are 
struggling to deliver modern health care effectively. The transformation of the health care 
system into integrated care needs to be supported using organizational health literacy and 
digital health.
As an example for chronic diseases, ICPs, MASK and POLLAR,21 in collaboration with 
professional and patient organizations in the field of allergy and airway diseases, 
are proposing real-world ICPs centered around the patient with rhinitis and asthma 
multimorbidity. These next-generation ICPs represent a cornerstone for the digital 
transformation of health.
There is a need to support the digital transformation of health and care with ICPs. An 
innovative patient-centered approach for ICPs has been proposed by the ARIA expert group 
for rhinitis and asthma multimorbidity to be scaled up to chronic diseases. Five aspects of 
ICPs have been developed in particular:
1)  Patient participation, health literacy and self-care through technology-assisted “patient 
activation.”29
2) ICP implementation by pharmacists.37
3)  Next-generation ARIA guidelines have assessed the GRADE recommendations in AR 
and asthma using RWE that includes not only randomized controlled trials on treat-
ment effects, but also evidence obtained by mHealth tools including MASK in order 
to confirm the efficiency or refine current recommendations. The MASK results have 
confirmed the feasibility of the project that will be used for other diseases.
4)  ARIA ICPs for allergen immunotherapy,67 including an innovative symptom-medication 
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score, based on the real-world data of MASK and the results of POLLAR for the 
prediction of the pollen season and pollutants.
5)  Embedding air pollution, aerobiology and novel approaches in ICPs during a meeting 
organized by the Finnish Institute of Health and Welfare (Presidency of the EU council, 
December 3-4, 2019).
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